A US FDA advisory committee will weigh the efficacy and safety of US WorldMeds LLC's Lucemyra (lofexidine) for managing symptoms of acute opioid withdrawal, as well as the adequacy of the evidence to support a novel claim – facilitation of completion of opioid discontinuation treatment.
The Psychopharmacologic Drugs Advisory Committee will meet March 27 to consider a dual indication for lofexidine, a new molecular entity...





